Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Constipation with bloating: a clinical approach to evaluation and management.

Annals of medicine·2026

Same author

Lessons learned from physician-performed high-resolution esophageal manometries.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2025

Same author

Non-invasive tests: Establishing efficacy for metabolic dysfunction-associated steatohepatitis beyond the biopsy-Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration.

Hepatology (Baltimore, Md.)·2025

Same author

Effect, Tolerability, and Safety of Exclusive Palatable Elemental Diet in Patients With Intestinal Microbial Overgrowth.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025

Same author

Radiographic Identification of Visceroptosis in Patients With Hypermobile Ehlers-Danlos Syndrome With Functional Gastrointestinal Symptoms Compared With Healthy Subjects.

Clinical and translational gastroenterology·2025

Same author

Comprehensive Association Analyses of Extraintestinal Manifestations in Inflammatory Bowel Disease.

Gastroenterology·2024

Search research articles

Related Experiment Video

Updated: Apr 5, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Hepatitis B: Working Towards a Cure.

Bianca W Chang¹, Aung Kaung, Lori Robbins

¹Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.

Current Gastroenterology Reports

|August 16, 2015

Summary

This summary is machine-generated.

Current hepatitis B treatments suppress the virus but lack durable cures. New therapies are emerging to achieve a functional cure for chronic hepatitis B infection.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Related Experiment Videos

Last Updated: Apr 5, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Area of Science:

Hepatology
Virology
Immunology

Background:

First-line oral therapies for hepatitis B virus (HBV) infection offer viral suppression and can improve liver health.
However, current treatment endpoints like hepatitis B e-antigen (HBeAg) loss and seroconversion are often not durable, leading to high rates of seroreversion.
Furthermore, achieving hepatitis B surface antigen (HBsAg) loss or seroconversion, a key goal for functional cure, occurs at low rates with existing treatments.

Purpose of the Study:

To review the defined endpoints for hepatitis B therapy.
To evaluate the durability of current treatment endpoints and the risks associated with long-term therapy.
To discuss the development of novel therapies aiming for a viral cure for hepatitis B.

Main Methods:

Literature review of current first-line oral therapies for hepatitis B.
Analysis of data on the durability of treatment endpoints (HBeAg loss, seroconversion, HBsAg loss).
Review of emerging therapeutic strategies for hepatitis B cure.

Main Results:

Oral therapies achieve viral suppression but rarely lead to durable HBsAg loss or seroconversion.
Recommended endpoints like HBeAg loss/seroconversion show high rates of seroreversion, necessitating ongoing monitoring.
Long-term hepatitis B treatment raises concerns regarding cost, potential side effects, and patient adherence.

Conclusions:

Current hepatitis B treatments are insufficient for achieving a durable cure.
The limitations of existing therapies highlight the need for new treatment strategies.
Evolving therapies offer promise for achieving a functional or complete cure for chronic hepatitis B.